

## Press Release

### Cellzome awarded €3.85m grant in Germany's High-Tech Initiative to Fund Top Regional Clusters

**Innovative *Kinobeads*<sup>™</sup> technology to be expanded to new areas of drug discovery and optimized for translational medicine studies**

**Heidelberg, November 24th 2008** - Cellzome is pleased to announce the award of a grant of up to € 3.85 million from the German government as part of an application of the biotech cluster Rhine-Neckar (BioRN).

The funds will be used to expand Cellzome's innovative technology platform into epigenetic target classes and subsequently its application to drug discovery projects in this area. In addition, Cellzome will be optimizing the current *Kinobeads*<sup>™</sup> platform for diagnostic and translational medicine studies, which will allow the monitoring of target-drug interactions directly in patient material. This will improve the predictability of the safety and efficacy of new drug candidates in the clinic. Overall, this grant enables Cellzome to extend its proteomics platform and to apply it even more broadly in drug discovery and development.

The grant, which will run for five years, is part of the High-Tech Initiative by the German Government and was awarded to five high-tech regions from 38 competing applications. The Rhine-Neckar Region around Heidelberg (the BioRN cluster), where Cellzome is based, was the only region which won a grant for life sciences/healthcare. In total, companies in the region will receive €40 million in funding over the next five years for projects based on cell-based and molecular medicine. Participants in the cluster include pharma companies such as Merck Serono and Roche, prominent research institutions and biotech companies.

Tim Edwards, CEO of Cellzome, said: "We are delighted to be chosen for this prestigious grant. It recognises Cellzome's outstanding technology platform, and enables us to broaden its scope and its range of applications together with our partners in the BioRN. This recognition from the German Government, and our recent major strategic alliance with GlaxoSmithKline, adds to our confidence that we can further build on our world-leading drug discovery technology, ultimately for the benefit of patients."

Dr. Christian Tidona, Managing Director of BioRN, said: "The combination of well established pharma companies, innovative biotech companies like Cellzome, and the availability of world-class research makes the Rhine-Neckar region very attractive for life sciences. With backing of this nature from the German government, we believe the region will become one of the leading biotech hubs in Europe."

- ends -

**For more information please contact:**

**Cellzome:**

Tim Edwards  
Chief Executive Officer  
Tel: +49 (0) 6221-137 57-100  
press@cellzome.com

**Media contact:**

Hogarth Partnership  
John Olsen/Melanie Toyne-Sewell  
Tel: +44 (0) 207 357 9477

**About Cellzome Inc.**

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by *Kinobeads*<sup>™</sup>, a proprietary technology for studying simultaneously multiple kinases in their native state, in relevant cell types.

Cellzome is applying its distinctive *Kinobeads*<sup>™</sup> technology to the discovery and development of novel, selective, small-molecule kinase inhibitors targeting key inflammatory mediators such as PI3K $\gamma$  and  $\delta$ , Zap-70, Jak3 and mTOR, as potential oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma.

In September 2008 Cellzome and GlaxoSmithKline announced a significant, worldwide, strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases, using Cellzome's *Kinobeads*<sup>™</sup> technology. In addition, Cellzome has a collaboration with Johnson & Johnson focused on the discovery of novel medicines for the treatment of Alzheimer's disease.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit [www.cellzome.com](http://www.cellzome.com).